Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals

Journal of Antimicrobial Chemotherapy

Volumn 62, Issue 6, 2008, Pages 1344-1355

  Dickinson, Laura ^a,b   Boffito, Marta ^c   Back, David J ^b   Khoo, Saye H ^b   Pozniak, Anton L ^c   Mugyenyi, Peter ^d   Merry, Concepta ^e   Autar, Reshma Saskia ^f   Burger, David M ^g   Aarons, Leon J ^h  

^a ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c Chelsea and Westminster Foundation Trust   (United Kingdom)

^d JOINT CLINICAL RESEARCH CENTRE   (Uganda)

^e TRINITY COLLEGE DUBLIN   (Ireland)

^f THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^g RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^h UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

NONMEM; Thailand; Uganda; UK; Variability

Indexed keywords

AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; RITONAVIR PLUS SAQUINAVIR; TENOFOVIR; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DISTRIBUTION VOLUME; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; POPULATION RESEARCH; THAILAND; UGANDA; UNITED KINGDOM;

ADULT; ANTI-HIV AGENTS; AREA UNDER CURVE; FEMALE; GREAT BRITAIN; HIV; HIV INFECTIONS; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, THEORETICAL; RITONAVIR; SAQUINAVIR; SERUM; THAILAND; UGANDA;

EID: 56649105357     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn399     Document Type: Article

References (34)

1. Plosker GL, Scott LJ. Saquinavir: A review of its use in boosted regimens for treating HIV infection. Drugs 2003; 63: 1299-324.
2. Back D, Gatti G, Fletcher C et al. Therapeutic drug monitoring in HIV infection: Current status and future directions. AIDS 2002; 16 Suppl 1: S5-37.
3. Back D, Gibbons S, Khoo S. An update on therapeutic drug monitoring for antiretroviral drugs. Ther Drug Monit 2006; 28: 468-73.
4. la Porte CJL, Back DJ, Blaschke T et al. Updated guideline to perform therapeutic drug monitoring for antiretroviral agents. Rev Antivir Ther 2006; 3: 4-14.
5. Fletcher CV, Jiang H, Brundage RC et al. Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359. J Infect Dis 2004; 189: 1176-84.
6. Valer L, De Mendoza C, De Requena DG et al. Impact of HIV genotyping and drug levels on the response to salvage therapy with saquinavir/ritonavir. AIDS 2002; 16: 1964-6.
7. Valer L, de Mendoza C, Soriano V. Predictive value of drug levels, HIV genotyping, and the genotypic inhibitory quotient (GIQ) on response to saquinavir/ritonavir in antiretroviral-experienced HIV-infected patients. J Med Virol 2005; 77: 460-4.
8. WHO. Scaling up Antiretroviral Therapy in Resource-Limited Settings: Treatment Guidelines for a Public Health Approach, 2003. http://www.who.int/3by5/publications/documents/arv_guidelines/en (25 April 2008, date last accessed).
9. Autar RS, Boffito M, Hassink E et al. Interindividual variability of once-daily ritonavir boosted saquinavir pharmacokinetics in Thai and UK patients. J Antimicrob Chemother 2005; 56: 908-13.
10. Autar RS, Ananworanich J, Apateerapong W et al. Pharmacokinetic study of saquinavir hard gel caps/ritonavir in HIV-1-infected patients: 1600/100 mg once-daily compared with 2000/100 mg oncedaily and 1000/100 mg twice-daily. J Antimicrob Chemother 2004; 54: 785-90.
11. Boffito M, Back D, Stainsby-Tron M et al. Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects. Br J Clin Pharmacol 2005; 59: 38-42.
12. Boffito M, Dickinson L, Hill A et al. Steady-state pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients. J Acquir Immune Defic Syndr 2004; 37 1376-84.
13. Boffito M, Dickinson L, Hill A et al. Pharmacokinetics of oncedaily saquinavir/ritonavir in HIV-infected subjects: Comparison with the standard twice-daily regimen. Antivir Ther 2004; 9: 423-9.
14. Boffito M, Kurowski M, Kruse G et al. Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen. AIDS 2004; 18: 1291-7.
15. Boffito M, Maitland D, Dickinson L et al. Boosted saquinavir hard gel formulation exposure in HIV-infected subjects: Ritonavir 100 mg once daily versus twice daily. J Antimicrob Chemother 2005; 55: 542-5.
16. Boffito M, Maitland D, Dickinson L et al. Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV type 1-infected individuals administered different atazanavir doses. AIDS Res Hum Retroviruses 2006; 22: 749-56.
17. Boffito M, Winston A, Fletcher C et al. Effect of a fat-containing meal on the pharmacokinetic (PK) profile of saquinavir 500 mg tablet/ ritonavir (SQV/r) 1000/100 mg BID in HIV-infected individuals. In: Abstracts of the Seventh International Workshop on Clinical Pharmacology of HIV Therapy, Lisbon, Portugal, 2006. Abstract 66, p. 60. Virology Education, Utrecht, Netherlands.
18. Cardiello PG, Monhaphol T, Mahanontharit A et al. Pharmacokinetics of once-daily saquinavir hard-gelatin capsules and saquinavir soft-gelatin capsules boosted with ritonavir in HIV-1-infected subjects. J Acquir Immune Defic Syndr 2003; 32: 375-9.
19. Coakley P, Merry C, Kityo C et al. The pharmacokinetics of saquinavir and ritonavir in Ugandan patients receiving ritonavir boosted saquinavir hard gel and soft gel. In: Abstracts of the Seventh International Congress on Drug Therapy in HIV Infection, Glasgow, UK, 2004. Abstract P277, p. 86-7. eJIAS: EJournal of the International AIDS Society, Quebec, Canada.
20. Dickinson L, Robinson L, Tjia J et al. Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 829: 82-90.
21. Droste JA, Verweij-Van Wissen CP, Burger DM. Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography. Ther Drug Monit 2003; 25: 393-9.
22. Kurowski M, Sternfeld T, Sawyer A et al. Pharmacokinetic and tolerability profile of twice-daily saquinavir hard gelatin capsules and saquinavir soft gelatin capsules boosted with ritonavir in healthy volunteers. HIV Med 2003; 4: 94-100.
23. Beal S, Sheiner LB. NONMEM User's Guide. Ellicott City, MD, USA: ICON Development Solutions, 1989-98.
24. Singh K, Dickinson L, Chaikan A et al. Pharmacokinetics and safety of saquinavir/ritonavir and omeprazole in HIV-infected subjects. Clin Pharmacol Ther 2007; 83: 867-72.
25. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981; 9: 503-12.
26. Vanhove GF, Kastrissios H, Gries JM et al. Pharmacokinetics of saquinavir, zidovudine, and zalcitabine in combination therapy. Antimicrob Agents Chemother 1997; 41: 2428-32.
27. Lavielle M, Mentre F. Estimation of population pharmacokinetic parameters of saquinavir in HIV patients with the MONOLIX software. J Pharmacokinet Pharmacodyn 2007; 34: 229-49.
28. Lunn DJ, Aarons L. The pharmacokinetics of saquinavir: A Markov chain Monte Carlo population analysis. J Pharmacokinet Biopharm 1998; 26: 47-74.
29. Trout H, Mentre F, Panhard X et al. Enhanced saquinavir exposure in human immunodeficiency virus type 1-infected patients with diarrhea and/or wasting syndrome. Antimicrob Agents Chemother 2004; 48 538-45.
30. Kappelhoff BS, van Leth F, MacGregor TR et al. Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study. Antivir Ther 2005; 10: 145-55.
31. Burger D, Boyd M, Duncombe C et al. Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients. J Antimicrob Chemother 2003; 51: 1231-8.
32. Roche Pharmaceuticals. Invirase® (saquinavir mesylate) capsules and tablets, US Prescribing Information, 2007.
33. Dickinson L, Boffito M, Khoo S et al. Pharmacokinetic analysis to assess forgiveness of boosted saquinavir regimens for missed or late dosing. J Antimicrob Chemother 2008; 62: 161-7.
34. Vrijens B, Tousset E, Rode R et al. Successful projection of the time course of drug concentration in plasma during a 1-year period from electronically compiled dosing-time data used as input to individually parameterized pharmacokinetic models. J Clin Pharmacol 2005; 45 461-7.